Titan Pharmaceuticals Announces Date of FDA Advisory Committee Review of Probuphine(R) for the Treatment of Opioid Dependence February 27, 2013
Probuphine(R) Receives FDA Priority Review Designation for Adult Patients With Opioid Dependence January 2, 2013
Titan Pharmaceuticals Licenses Exclusive Probuphine(R) Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals December 17, 2012
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results August 8, 2012
Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment for Parkinson's Disease July 9, 2012
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results May 9, 2012
